作者:老萝卜头近日,中国生物制药(01177.HK)以约5亿美元净代价,将礼新医药收入麾下。然而,资本市场对此却异常冷静,公告发布次日,中国生物制药股价仅微涨1.1%。这份“矜持”的背后是一家医药企业的核心命题——曾凭借首仿药登顶千亿市值的传统巨头,试图用一场天价收购填补创新断层时,这张昂贵的“药方”究竟是“灵丹妙药”,还是新困境的开始?01 68亿元收购礼新医药的战略意图2025年7月15日,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.